AXQ Capital’s Protara Therapeutics TARA Stock Holding History

AXQ Capital’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-13,002	Closed	-$67.7K	–	1339
2026 Q1	$67.7K	Buy	13,002 +2,187	+20%	+$12.9K	0.01%	911
2025 Q4	$57.6K	Buy	+10,815	New	+$60.1K	0.01%	685

Other funds holding TARA

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

AXQ Capital's TARA Position: Q2 2026 in Review

AXQ Capital sold out of Protara Therapeutics (TARA) in Q2 2026, closing a stake of 13,002 shares — an estimated $67.7K sold.

AXQ Capital first reported a position in TARA in Q4 2025 and held it in 2 quarters. The position peaked at $67.7K in Q1 2026. 120 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

AXQ Capital reported no remaining Protara Therapeutics position as of Q2 2026 after selling out during the quarter.
AXQ Capital sold 13,002 Protara Therapeutics shares in Q2 2026, an estimated $67.7K.
AXQ Capital first reported a position in Protara Therapeutics in Q4 2025 and held it in 2 quarters.
AXQ Capital's Protara Therapeutics position peaked at $67.7K in Q1 2026.
120 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on AXQ Capital's 13F filing for Q2 2026, filed 6 Aug 2026.